-
1
Treatment advances in Vitiligo: An Updated Review
Published 2025-01-01Subjects: Get full text
Article -
2
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
Published 2025-02-01Subjects: Get full text
Article -
3
Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
Published 2025-01-01Subjects: “…Hand dermatitis, Hand Eczema, Upadacitinib, Janus kinase inhibitor.…”
Get full text
Article -
4
Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
Published 2025-01-01Subjects: Get full text
Article -
5
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
Published 2025-02-01Subjects: Get full text
Article -
6
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway
Published 2025-01-01Subjects: Get full text
Article -
7
Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
Published 2025-12-01Subjects: Get full text
Article -
8
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Published 2025-02-01Subjects: Get full text
Article -
9
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
Published 2023-07-01Subjects: Get full text
Article -
10
Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model
Published 2025-01-01Subjects: Get full text
Article -
11
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
Published 2025-01-01Subjects: Get full text
Article -
12
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
Published 2025-02-01Subjects: “…Janus kinase (JAK) inhibitors…”
Get full text
Article -
13
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Published 2025-12-01Subjects: Get full text
Article -
14
-
15
-
16
-
17